KYOTO & FUJISAWA, Japan– xFOREST Therapeutics Co., Ltd. and Axcelead Drug Discovery Partners, Inc. announced the start of a joint research collaboration to advance RNA structure-targeted small molecule therapeutics for multiple diseases.
xFOREST has developed its proprietary FOREST Technologies platform, which combines a custom RNA structure library with high-throughput screening to identify small molecules that target RNA structures. These regions have historically been considered “undruggable” by traditional approaches. Alongside its own R&D, the company has partnered with global pharmaceutical firms to strengthen its role in the RNA-targeted drug discovery field.
Axcelead DDP, a drug discovery solutions provider with broad pharmaceutical R&D expertise, is investing in RNA-targeted small molecule research as part of its focus on next-generation therapeutic modalities. The company provides integrated discovery services and has expanded its capabilities through both internal development and partnerships.
Under the agreement, the two companies will enhance the RNA structure-targeted small molecule discovery platform, with the goal of improving efficiency and generating more viable drug candidates. xFOREST will retain exclusive rights to develop and commercialize selected compounds, while Axcelead DDP will receive milestone payments tied to development progress.
“We are thrilled to begin this new joint research initiative with Axcelead DDP,” said Shunichi Kashida, Ph.D., Representative Director, President and CEO of xFOREST. “By combining Axcelead DDP’s extensive expertise in small molecule drug discovery with our advanced RNA analysis technologies, we are confident that we can accelerate the development of innovative RNA-targeted therapeutics, including those directed at mRNA and pre-mRNA.”
Kengo Okada, Ph.D., Representative Director, President and CEO of Axcelead DDP, added: “We are delighted to embark on this joint research with xFOREST, a leading company in RNA structure-targeted small molecule drug discovery. By strengthening our RNA drug discovery platform, we aim to provide high-quality solutions to clients facing complex research challenges and contribute to the creation of innovative medicines.”
